In the rapidly evolving landscape of the human microbiome, Eubacterium rectale has emerged as a critical functional unit for maintaining intestinal homeostasis and systemic health. As a primary producer of butyrate—a short-chain fatty acid (SCFA) essential for gut barrier integrity and immune modulation—E. rectale represents a high-value candidate for Live Biotherapeutic Product (LBP) development.
Our CRO provides an integrated, end-to-end preclinical research platform specifically optimized for the cultivation, characterization, and therapeutic evaluation of E. rectale. By bridging the gap between basic microbiology and clinical readiness, we empower biotech and pharmaceutical innovators to de-risk their pipelines and accelerate the delivery of microbiome-based therapies to patients in need.
Overview: Understanding Eubacterium rectale
Eubacterium rectale is one of the most abundant and ecologically significant members of the human gut microbiota, often comprising up to 13% of the total fecal microbial community in healthy individuals. Belonging to the Lachnospiraceae family (Clostridiales cluster XIVa), it is a Gram-positive, anaerobic bacterium renowned for its specialized metabolic pathways.
Key Biological Roles:
-
Butyrate Synthesis: It converts acetate and lactate into butyrate, the primary energy source for colonocytes.
-
Starch Degradation: It possesses a complex repertoire of enzymes to break down resistant starches and dietary fibers.
-
Anti-Inflammatory Signaling: Through SCFA production and direct interaction with the gut-associated lymphoid tissue (GALT), it helps suppress pro-inflammatory cytokines like IL-6 and TNF-α.
Our Preclinical Research Services
Navigating the complexities of anaerobic live biotherapeutics requires specialized expertise. We offer a full suite of preclinical services tailored to E. rectale:
-
Gnotobiotic Mouse Models: Utilizing germ-free mice to study the colonization and therapeutic impact of E. rectale in isolation.
-
Disease-Specific Models: Efficacy testing in DSS-induced colitis, high-fat diet (HFD) obesity, and syngeneic tumor models.
-
PK/PD for LBPs: Tracking strain survival, engraftment, and metabolite production in the host gut.
Products for Preclinical Research
To support your internal R&D, we provide high-quality, research-grade materials:
-
Certified Strains: Fully characterized E. rectale type strains and proprietary isolates.
-
Reference Standards: Genomic DNA and RNA standards for qPCR-based quantification in fecal samples.
Research Applications in Disease Treatment
Current research highlights E. rectale as a potent "sentinel" of gut health. Its depletion is a hallmark of several metabolic and inflammatory conditions, making it a primary target for reconstitution therapies.
Improves insulin sensitivity and reduces low-grade systemic inflammation by restoring SCFA levels.
Strengthens the mucosal barrier and promotes T-regulatory (Treg) cell differentiation to alleviate colitis.
Recent studies suggest E. rectale enriches the gut environment to enhance the efficacy of Anti-PD-1 checkpoint inhibitors.
Acts as a systemic immune modulator; its presence is inversely correlated with the severity of psoriatic arthritis.
Produces metabolites that inhibit oncogenic signaling pathways and promote DNA repair in intestinal cells.
Our Advantages
Anaerobic Specialists
Our laboratories are equipped with state-of-the-art anaerobic chambers and bioreactors specifically designed for "difficult-to-culture" Clostridiales.
Integrated Multi-Omics
We combine metagenomics, transcriptomics, and metabolomics to provide a holistic view of how the strain functions within the host.
Regulatory Insight
All preclinical data are generated following guidelines compatible with IND (Investigational New Drug) submissions for LBPs.
Accelerated Timelines
Our established models for E. rectale allow for rapid study initiation and data turnaround.
The transition from "correlative" microbiome data to "causative" therapeutic intervention is the next frontier of medicine. Eubacterium rectale stands at the center of this shift, offering a natural, potent solution for metabolic and inflammatory dysbiosis.
At Creative Biolabs, we believe that the success of a Live Biotherapeutic depends on the precision of its preclinical foundation. By choosing our specialized E. rectale research service, you are not just outsourcing a study; you are gaining a partner dedicated to the scientific integrity and clinical success of your microbiome therapy. Let us help you unlock the full therapeutic potential of the gut's most vital inhabitants.
Would you like me to generate a specific technical protocol for an in vivo efficacy study using E. rectale in a colitis model?
Frequently Asked Questions (FAQs)
Is Eubacterium rectale safe for human consumption?
As a common commensal found in healthy humans, it has a high safety profile. However, for LBP development, we conduct rigorous genomic screening to ensure no transferable antibiotic resistance or toxins are present.
Can E. rectale survive the acidic environment of the stomach?
Like most non-spore-forming anaerobes, it is sensitive to low pH. Our services include the development of specialized encapsulation and enteric coating technologies to ensure viable delivery to the colon.
How do you quantify E. rectale in complex fecal samples?
We utilize high-sensitivity strain-specific qPCR primers and metagenomic shotgun sequencing to track engraftment levels in vivo.
